E. Falcó

763 total citations
37 papers, 292 citations indexed

About

E. Falcó is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, E. Falcó has authored 37 papers receiving a total of 292 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in E. Falcó's work include Colorectal Cancer Treatments and Studies (20 papers), Gastric Cancer Management and Outcomes (11 papers) and Hepatocellular Carcinoma Treatment and Prognosis (6 papers). E. Falcó is often cited by papers focused on Colorectal Cancer Treatments and Studies (20 papers), Gastric Cancer Management and Outcomes (11 papers) and Hepatocellular Carcinoma Treatment and Prognosis (6 papers). E. Falcó collaborates with scholars based in Spain, Italy and United States. E. Falcó's co-authors include Enrique Aranda, Javier Gállego, José Luís Zamora Manzano, Ana Ruiz‐Casado, Jorge Aparicio, F. Espósito, P. Escudero, Ana Fernández Montés, Encarnación González‐Flores and María Alsina and has published in prestigious journals such as Journal of Clinical Oncology, Free Radical Biology and Medicine and Annals of Oncology.

In The Last Decade

E. Falcó

35 papers receiving 288 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Falcó Spain	10	176	136	65	51	44	37	292
Masashi Fujii Japan	11	221 1.3×	144 1.1×	81 1.2×	34 0.7×	44 1.0×	45	297
Maria Grazia Rodriquenz Italy	10	149 0.8×	97 0.7×	62 1.0×	77 1.5×	51 1.2×	27	279
Keita Uchino Japan	12	215 1.2×	151 1.1×	59 0.9×	86 1.7×	39 0.9×	40	357
Jean Philippe Metges France	8	224 1.3×	124 0.9×	85 1.3×	110 2.2×	76 1.7×	23	343
Sabina Murgioni Italy	11	214 1.2×	145 1.1×	85 1.3×	73 1.4×	76 1.7×	38	361
Antonio Pellino Italy	6	118 0.7×	85 0.6×	111 1.7×	56 1.1×	59 1.3×	10	224
E. Goode United Kingdom	7	177 1.0×	106 0.8×	51 0.8×	108 2.1×	34 0.8×	12	325
Chun-yu Huang China	10	179 1.0×	164 1.2×	121 1.9×	143 2.8×	72 1.6×	13	429
Rie Nakatsuka Japan	9	86 0.5×	71 0.5×	65 1.0×	76 1.5×	23 0.5×	21	240
Floriana Nappo Italy	7	141 0.8×	131 1.0×	80 1.2×	56 1.1×	52 1.2×	21	262

Countries citing papers authored by E. Falcó

Since Specialization

Citations

This map shows the geographic impact of E. Falcó's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Falcó with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Falcó more than expected).

Fields of papers citing papers by E. Falcó

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Falcó. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Falcó. The network helps show where E. Falcó may publish in the future.

Co-authorship network of co-authors of E. Falcó

This figure shows the co-authorship network connecting the top 25 collaborators of E. Falcó. A scholar is included among the top collaborators of E. Falcó based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Falcó. E. Falcó is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Montés, Ana Fernández, Vicente Alonso Orduña, Elena Asensio, et al.. (2023). The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer. The Oncologist. 28(10). e902–e909. 4 indexed citations

García‐Carbonero, Rocio, Carles Pericay, Ana Fernández Montés, et al.. (2023). Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain. Clinical & Translational Oncology. 26(4). 864–871. 1 indexed citations

Pericay, Carles, Ana Fernández Montés, Vicente Alonso Orduña, et al.. (2023). Real-World Outcomes in Patients with Metastatic Colorectal Cancer in Spain: The RWD-ACROSS Study. Cancers. 15(18). 4603–4603. 3 indexed citations

Vergote, Ignace, Antonio Casado, Annouschka Laenen, et al.. (2023). Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer. Gynecologic Oncology. 174. 80–88. 5 indexed citations

Torrens‐Mas, Margalida, Daniel Gabriel Pons, E. Falcó, et al.. (2022). Mitochondrial Function Differences between Tumor Tissue of Human Metastatic and Premetastatic CRC. Biology. 11(2). 293–293. 9 indexed citations

Torrens‐Mas, Margalida, E. Falcó, Teresa de Souza Fernandez, et al.. (2022). Inflammation- and Metastasis-Related Proteins Expression Changes in Early Stages in Tumor and Non-Tumor Adjacent Tissues of Colorectal Cancer Samples. Cancers. 14(18). 4487–4487. 1 indexed citations

Falcó, E., Teresa de Souza Fernandez, Margalida Torrens‐Mas, et al.. (2020). Antioxidant enzymes change in different non-metastatic stages in tumoral and peritumoral tissues of colorectal cancer. The International Journal of Biochemistry & Cell Biology. 120. 105698–105698. 21 indexed citations

Carrato, Alfredo, Manuel Benavides, Bartomeu Massutí, et al.. (2019). First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). BMC Cancer. 19(1). 533–533. 12 indexed citations

García‐Alfonso, Pilar, Manuel Benavides, E. Falcó, et al.. (2018). Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial). The Oncologist. 23(11). 1271–e128. 10 indexed citations

10.

Alonso, Vicente, P. Escudero, Carlos Fernández-Martos, et al.. (2018). Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients. Neoplasia. 20(7). 678–686. 9 indexed citations

11.

Torrens‐Mas, Margalida, Daniel Gabriel Pons, E. Falcó, et al.. (2018). Non-tumor adjacent tissue of advanced stage from CRC shows activated antioxidant response. Free Radical Biology and Medicine. 126. 249–258. 8 indexed citations

12.

Salazar, Ramón, Daniel Azuara, José María Viéitez, et al.. (2017). ULTRA clinical trial: Prospective comparative clinical outcome analysis of three different RAS/BRAF sensitivity mutational cut-offs. A Phase II study of the Spanish TTD Group. Annals of Oncology. 28. v185–v186. 1 indexed citations

13.

Torrens‐Mas, Margalida, Daniel Gabriel Pons, E. Falcó, et al.. (2017). Differences in antioxidant enzymes in tumour tissue and non-tumour adjacent tissue in colorectal cancer patients at different stages (III and IV). Free Radical Biology and Medicine. 108. S88–S88. 1 indexed citations

14.

Alonso, Vicente, Javier Gállego, José Ramón Rodríguez, et al.. (2016). Prospective evaluation of BRAF, PI3K and PTEN as predictive and prognostic biomarkers in first-line advanced KRAS wild-type colorectal cancer treated with FOLFOX or FOLFIRI plus bi-weekly cetuximab. GEMCAD 10-02. Annals of Oncology. 27. vi178–vi178.

15.

Vera, Ruth, María Luisa Gómez Dorronsoro, Juan Ramón Ayuso, et al.. (2015). Correlation between RECIST-conventional imaging techniques, morphologic response by CT and histopathologic response, in hepatic metastasis secondary to colorectal cancer: The AVAMET study.. Journal of Clinical Oncology. 33(15_suppl). e14656–e14656. 1 indexed citations

16.

Gómez-Martín, Carlos, Antonio Irigoyen López, Raquel Serrano, et al.. (2012). Incidence of hand–foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. Clinical & Translational Oncology. 14(9). 689–697. 6 indexed citations

17.

Cuadrado, A., José Noguera, Carlos Dolz, et al.. (2011). Multidisciplinary approach and multimodal therapy in resected pancreatic cancer: Observational study. Revista Española de Enfermedades Digestivas. 103(1). 5–12. 4 indexed citations

18.

López, R.A. Medina, et al.. (1995). Tratamiento de los ganglios regionales en el carcinoma escamoso de pene.. Revista Argentina de Urología. 60(1). 30–34. 1 indexed citations

19.

Falcó, E., et al.. (1993). [Caroli's disease associated with cholangiocarcinoma. A case of our own observation].. PubMed. 48(17). 961–4. 5 indexed citations

20.

Celoria, G, et al.. (1992). [Idiopathic and torsion-induced omental infarct: case reports and a review of the literature].. PubMed. 12(11-12). 569–71. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact